Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Cantor Fitzgerald

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 191.67% from the company’s current price. A […]

Related Keywords

Piper Sandler ,Taysha Gene Therapies Inc ,Dynamic Technology Lab Private Ltd ,Maven Securities ,Cantor Fitzgerald ,Canaccord Genuity Group ,Howard Capital Management Inc ,Victory Capital Management Inc ,Taysha Gene Therapies Company Profile ,Capital Investment Advisors ,Needham Company ,Taysha Gene Therapies ,Get Free Report ,Genuity Group ,Chardan Capital ,Gene Therapies ,Capital Management ,Technology Lab Private Ltd ,Investment Advisors ,Taysha Gene Therapies Daily ,